Literature DB >> 21274858

Health care reform: how personalized medicine could help bundling of care for liver diseases.

Lopa Mishra1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21274858      PMCID： PMC3444166          DOI： 10.1002/hep.24144

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  19 in total

1.  Clinical application of pharmacogenetics.

Authors:  B B Spear; M Heath-Chiozzi; J Huff
Journal:  Trends Mol Med       Date:  2001-05       Impact factor: 11.951

2.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

3.  US Health Care Reform and Transplantation, Part II: impact on the public sector and novel health care delivery systems.

Authors:  D A Axelrod; D Millman; M M Abecassis
Journal:  Am J Transplant       Date:  2010-10       Impact factor: 8.086

4.  Management of hepatocellular carcinoma.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

5.  The Personalized Medicine Coalition: goals and strategies.

Authors:  Edward Abrahams; Geoffrey S Ginsburg; Mike Silver
Journal:  Am J Pharmacogenomics       Date:  2005

Review 6.  Pharmacogenomics and the drug discovery pipeline: when should it be implemented?

Authors:  Michelle A Penny; Duncan McHale
Journal:  Am J Pharmacogenomics       Date:  2005

7.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

8.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

9.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

10.  CardioVascular Care Providers. A pioneer in bundled services, shared risk, and single payment.

Authors:  C Edmonds; G L Hallman
Journal:  Tex Heart Inst J       Date:  1995
View more
  1 in total

1.  Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury.

Authors:  Denada Dibra; Jeffry Cutrera; Xueqing Xia; Bhaskar Kallakury; Lopa Mishra; Shulin Li
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.